Overview

Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This is a 3-week study to evaluate FEV1 following treatment with drugs in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Montelukast